Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia
- PMID: 6419311
- DOI: 10.1093/clinids/5.supplement_5.s852
Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia
Abstract
Three cell wall-derived Pseudomonas aeruginosa vaccines were evaluated for their capacity to provide protection from experimental pseudomonas pneumonia in guinea pigs. Two vaccines, Pseudogen, a heptavalent lipopolysaccharide vaccine, and PEV-01, a polyvalent glycine-EDTA cell wall extract, each produced hemagglutinating, opsonic, and serum bactericidal antibodies in guinea pigs. Significant protection from fatal hemorrhagic pneumonia was conferred by vaccination with these products. Purified, high-molecular weight polysaccharide vaccine was a less potent immunogen in guinea pigs and provided less protection from pneumonia. Protection from fatal pneumonia in vaccinees correlated with more rapid clearance of viable P. aeruginosa from lung tissue during the first 6 hr of infection. It appears that active immunization with certain cell wall-derived pseudomonas antigens can provide protection against experimental pseudomonas pneumonia.
Similar articles
-
Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa.J Infect Dis. 1979 Jul;140(1):73-80. doi: 10.1093/infdis/140.1.73. J Infect Dis. 1979. PMID: 110888
-
Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections.Infect Immun. 1979 Sep;25(3):1029-34. doi: 10.1128/iai.25.3.1029-1034.1979. Infect Immun. 1979. PMID: 115786 Free PMC article.
-
Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.Rev Infect Dis. 1986 Jul-Aug;8 Suppl 4:S426-33. doi: 10.1093/clinids/8.supplement_4.s426. Rev Infect Dis. 1986. PMID: 2944209
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
-
Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Expert Rev Vaccines. 2005 Oct;4(5):645-56. doi: 10.1586/14760584.4.5.645. Expert Rev Vaccines. 2005. PMID: 16221066 Review.
Cited by
-
Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.Infect Immun. 2001 Apr;69(4):2223-9. doi: 10.1128/IAI.69.4.2223-2229.2001. Infect Immun. 2001. PMID: 11254577 Free PMC article.
-
Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.Infect Immun. 1994 Jan;62(1):308-12. doi: 10.1128/iai.62.1.308-312.1994. Infect Immun. 1994. PMID: 8262644 Free PMC article.
-
Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.Infect Immun. 1986 Oct;54(1):239-44. doi: 10.1128/iai.54.1.239-244.1986. Infect Immun. 1986. PMID: 3093385 Free PMC article.
-
Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.Springer Semin Immunopathol. 1993;15(2-3):235-46. doi: 10.1007/BF00201104. Springer Semin Immunopathol. 1993. PMID: 7504840 No abstract available.
-
Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.Infect Immun. 1994 Jun;62(6):2257-69. doi: 10.1128/iai.62.6.2257-2269.1994. Infect Immun. 1994. PMID: 8188347 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical